Biomarin Acquires Prosensa In Deal Valued Up To $840 Million

SAN RAFAEL (TheStreet) -- BioMarin Pharmaceuticals is expanding its reach into the market for rare disease therapies with a deal to buy Prosensa Holding for up to $840 million, the companies announced Monday. The deal is a gamble of sorts for Biomarin, which is betting that its experience and expertise in securing approvals for so-called "orphan disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy, despite mixed results from clinical trials.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News